Genix Pharmaceuticals Corporation(GENPF)
USD --+0.00%
Reward24Low
Risk74High
📊75%Data
Revenue down 63% YoY
GENPF
+0.0 · +0.00%
USD · PINK
Genix Pharmaceuticals Corporation | Healthcare
Earnings Deterioration
Market Cap:835060
ℹ️
Reward Rating
24
Low
Bottom 1% (model universe)
75% data coverage
ℹ️
Risk Rating
74
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on GENPF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Genix Pharmaceuticals Corporation?

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada.

GENPF · Verdict

Limited reward · high risk

GENPF's standout is volatility; valuation and balance sheet weigh on the picture.

Based on 88% data coverage

GENPF · Verdict

What’s working & what to watch

Strengths 1

  • Volatility80/100

    Top decile vs peers

Watchouts 5

  • Valuation0/100

    Weak vs peers

  • Balance sheet6/100

    Interest covered 0.4×

  • Cash flow7/100

    -4625% free-cash-flow margin

  • Growth18/100

    Earnings -64.6% CAGR

  • Profitability21/100

    -1807% net margin · -661% ROE

Model-based scoring. For information only — not financial advice.

What is Genix Pharmaceuticals Corporation?

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 835.06K.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (24)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap835.06K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.04
52 Week Low0.0138
Last AnnualOctober
IPO DateN/A
IncorporatedUSA
Shares Outstanding59M
No. of EmployeesN/A
IndustryDrug Manufacturers - Specialty & Generic
ExchangePINK
Beta0.486
CurrencyUSD · Reports in CAD